Novartis AG ADR Stock
€99.60
Your prediction
Novartis AG ADR Stock
Pros and Cons of Novartis AG ADR in the next few years
Pros
Cons
Performance of Novartis AG ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Novartis AG ADR | -2.440% | -0.200% | -3.301% | -3.301% | 5.508% | 18.571% | 42.286% |
| Roche Holding AG ADR | 0.360% | -0.386% | 1.462% | -6.104% | 5.388% | -13.434% | -4.069% |
| Bayer AG ADR | -2.840% | -0.725% | 4.580% | 3.008% | 38.105% | -52.098% | -51.071% |
| Astrazeneca ADR | -5.190% | 2.381% | 8.403% | -12.245% | 0.781% | -0.463% | 36.076% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon reviewing the financial statements of Novartis (NASDAQ: NVS), a prominent player in the pharmaceutical industry, the general impression suggests that the company maintains a solid financial standing. With substantial total assets, a strong revenue base, and a broad diversification through various investments, Novartis appears to be a robust organization in terms of financial health.
Cash Position: Novartis has maintained a considerable cash position in recent years, end of 2022 standing at $7.52B. A strong liquidity profile allows the company to invest in research and development or pursue mergers and acquisitions to drive future growth.
Increasing Revenue: The total revenue increased from $49.9B in 2020 to $52.9B in 2021 and further up to $58.2B in 2022. This growth suggests that the company is effectively generating business, increasing market share, and expanding its product portfolio.
Comments
News
Industry-Wide Tariffs Loom Over the Healthcare Sector. Here Are 2 Stocks That Can Weather the Storm.
President Donald Trump's trade policies have caused tumult on Wall Street. The president has pushed for aggressive tariffs on imported goods in an attempt to bring manufacturing jobs back to the
These 2 Top Dividend Stocks Are Making Moves to Avoid the Impact of Tariffs: Are They Buys?
President Donald Trump's macroeconomic policies are taking center stage on Wall Street. The 47th U.S. president has decided to implement aggressive tariffs on imported goods from most countries
2 High-Yield Dividend Stocks to Hold Through 2025 and Beyond
If there were an official hierarchy of qualities that dividend seekers should consider before investing in a stock, a company's underlying business would almost certainly come ahead of its yield